This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global CNS Therapeutics Industry

NEW YORK, March 25, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Global CNS Therapeutics Industry

This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia and ADHD). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018.

The report profiles 127 companies including many key and niche players such as AbbVie Inc., Alkermes Plc, Amneal Pharmaceuticals, LLC, Aspen Pharmacare Holdings Limited, AstraZeneca Plc, BEACON Pharmaceutical Limited, BIAL Group, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Elan Corporation Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Fabre-Kramer Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi S.A, Shire Plc, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and UCB Group.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3CNS Disorders I-3Anti-Alzheimer's Drugs I-3Anti-Parkinson's Drugs I-4Anti-Epilepsy Drugs I-4Pain Management Drugs I-4Anti-Psychotics Drugs I-5Bipolar disorder I-5Schizophrenia I-5Anti-Depressants Drugs I-5Others I-6Attention Deficit Hyperactivity Disorder I-6Multiple Sclerosis I-6Insomnia I-6Restless Legs Syndrome I-7Anxiety I-7

1 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs